Incidence of inhibitor development in a group of young hemophilia A patients treated exclusively with lyophilized cryoprecipitate.
The incidence of neutralizing isoantibody formation to infused factor VIII in a cohort of 67 hemophilia A patients, born between January 1, 1971 and April 30, 1990, who had been treated exclusively with lyophilized cryoprecipitate, was 6% (5.3 per 1,000 patient years of observation). The age-dependent cumulative risk was 4.6% at 4 years of age and 6.7% at 8 years of age. Recent reports in patients treated with a variety of more pure concentrates show a much higher incidence of inhibitor formation and tend to be used as a reference when new concentrates are introduced. We believe that a patient group, such as the one studied here, is a more suitable reference population because these patients have been exclusively treated with a single factor VIII preparation.
Peerlinck
K
K
Center for Thrombosis and Vascular Research, University of Leuven, Belgium.
Rosendaal
F R
FR
Vermylen
J
J
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000293:Adolescent; D000328:Adult; D011232:Chemical Precipitation; D002648:Child; D002675:Child, Preschool; D005169:Factor VIII / Q000276:immunology* / Q000627:therapeutic use; D005612:Freeze Drying; D005615:Freezing; D006679:HIV Seropositivity; D006467:Hemophilia A / Q000150:complications / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D007518:Isoantibodies / Q000097:blood*
D007518:Isoantibodies; D005169:Factor VIII